UPLIFT (ENGOT-ov67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin, a NaPi2b-directed dolaflexin antibody-drug conjugate, in platinum-resistant ovarian cancer

被引：0

作者：

Richardson, Debra ^{[1
]}

Iyer, Gopa ^{[2
]}

Schmid, Anita ^{[3
]}

Palma, Norma ^{[3
]}

Navarro, Willis ^{[3
]}

Ahnert, Jordi Rodon ^{[4
]}

机构：

[1] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Aadi Biosci, Pacific Palisades, CA USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

GYNECOLOGIC ONCOLOGY | 2024年 / 190卷

关键词：

D O I：

10.1016/j.ygyno.2024.07.424

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2126

引用

页码：S285 / S286

页数：2

共 24 条

[21] A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC). [J].

Banerjee, Susana N. ;

Oza, Amit M. ;

Birrer, Michael J. ;

Hamilton, Erika Paige ;

Hasan, Jurjees ;

Leary, Alexandra ;

Moore, Kathleen N. ;

Mackowiak-Matejczyk, Beata ;

Pikiel, Joanna ;

Ray-Coquard, Isabelle ;

Trask, Peter ;

Lin, Kedan ;

Vaze, Anjali ;

Choi, YounJeong ;

Marsters, Jim ;

Maslyar, Daniel J. ;

Lemahieu, Vanessa ;

Wang, Yulei ;

Humke, Eric William ;

Liu, Joyce F. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[22] A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non- small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC). [J].

Gordon, Michael S. ;

Gerber, David E. ;

Infante, Jeffrey R. ;

Xu, Jian ;

Shames, David S. ;

Choi, Younjeong ;

Kahn, Robert S. ;

Lin, Kedan ;

Wood, Katie ;

Maslyar, Daniel J. ;

Burris, Howard A. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

[23] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study. [J].

O'Malley, David M. ;

Martin, Lainie P. ;

Gilbert, Lucy ;

Vergote, Ignace ;

Matulonis, Ursula A. ;

Birrer, Michael J. ;

Castro, Cesar Martin ;

Malek, Karim S. ;

Gonzalez-Martin, Antonio ;

Moore, Kathleen N. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[24] Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial [J].

Bardia, A. ;

Messersmith, W. A. ;

Kio, E. A. ;

Berlin, J. D. ;

Vahdat, L. ;

Masters, G. A. ;

Moroose, R. ;

Santin, A. D. ;

Kalinsky, K. ;

Picozzi, V ;

O'Shaughnessy, J. ;

Gray, J. E. ;

Komiya, T. ;

Lang, J. M. ;

Chang, J. C. ;

Starodub, A. ;

Goldenberg, D. M. ;

Sharkey, R. M. ;

Maliakal, P. ;

Hong, Q. ;

Wegener, W. A. ;

Goswami, T. ;

Ocean, A. J. .

ANNALS OF ONCOLOGY, 2021, 32 (06) :746-756

← 1 2 3 →